Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea

scientific article published in June 2013

Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1001714932
P356DOI10.1007/S00408-013-9481-5
P698PubMed publication ID23728990

P50authorJi Ye JungQ40606561
Moo Suk ParkQ59688292
Song Yee KimQ60311732
Young Sam KimQ61822423
Joon ChangQ63809586
Se Kyu KimQ124799196
P2093author name stringEun Young Kim
Sang Kook Lee
Young Ae Kang
P2860cites workTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentQ28191546
Infliximab for induction and maintenance therapy for ulcerative colitisQ28285876
Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene?Q28305093
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupQ29616063
Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice.Q33696833
Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapyQ33836681
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Q34081925
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statementQ34660076
Spread of nontuberculous mycobacteria from 1993 to 2006 in Koreans.Q34884737
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic reviewQ36689393
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseasesQ36727850
Tumor necrosis factor and tuberculosisQ36821985
Tumour necrosis factor antagonists: structure, function, and tuberculosis risksQ37298854
Mycobacterial disease in patients with rheumatic diseaseQ37335860
TNF-alpha in tuberculosis: a cytokine with a split personalityQ37411568
Diagnosis and treatment of lung infection with nontuberculous mycobacteriaQ37420341
Nontuberculous mycobacteria and the lung: from suspicion to treatmentQ37727884
Nontuberculous mycobacterial lung diseasesQ37776904
Tuberculosis and anti-TNF treatment: experience of a central London hospitalQ37802766
Nontuberculous mycobacteria infection in solid organ transplant recipientsQ37898048
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance reportQ45180236
Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assayQ46703434
Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea.Q47593172
Granulomatous infectious diseases associated with tumor necrosis factor antagonistsQ47648712
BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.Q53621736
Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockersQ57212364
Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections NetworkQ81103797
Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden countryQ81823239
Mycobacterial infections in the era of modern biologic agentsQ83541778
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectSouth KoreaQ884
P304page(s)565-571
P577publication date2013-06-01
P1433published inLungQ15765075
P1476titleMycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea
P478volume191

Reverse relations

cites work (P2860)
Q91604218A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment
Q55491389Clinical outcomes of endoscopic mucosal resection for rectal neuroendocrine tumor.
Q85965096Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area
Q26748674Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease
Q37231860Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study
Q35787739Experimental Reactivation of Pulmonary Mycobacterium avium Complex Infection in a Modified Cornell-Like Murine Model.
Q35822931High Latent TB Infection Rate and Associated Risk Factors in the Eastern China of Low TB Incidence
Q59131827Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease
Q54506955Non-tuberculous mycobacterial infections in psoriasis patients treated with biologics.
Q38353491Nontuberculous mycobacteria infections in immunosuppressed hosts
Q41549099Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor
Q38611360Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.
Q35028459The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
Q39449936Tuberculosis and biologics in rheumatology: India - A special situation.

Search more.